Agoracom Blog Home

Posts Tagged ‘Marijuana’

THE MOST EMOTIONAL AGORACOM INTERVIEW EVER: Green Beret Recovers From Life-Threatening #PTSD, Takes #CBD To #Military And Law Enforcement With #Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:12 AM on Tuesday, March 3rd, 2020

Adam Smith is a bad ass Green Beret with nearly 17 years of service to his country …. who put a gun in his mouth when his PTSD simply became too much to handle.  Pharma drugs prescribed by doctors were actually making his problems worse and he had nowhere to turn.    

More than just a story, watch his 2-minute video within our video interview with him and Hollister Biosciences CEO, Carl Saling.  Be prepared.  

Thankfully, a fellow soldier told him about CBD and Smith experienced firsthand how CBD can help retired and active-duty (military and law enforcement) ease their physical and mental issues – especially those who suffer from PTSD and TBI (Traumatic Brain Injury).    

The results were so dramatic that Smith’s new mission was to get CBD into the hands of as many soldiers as possible.  He founded Tactical Relief and the rest is history. Tactical Relief creates, promotes and sells the highest quality and “most patriotic” CBD oils in the country.     

Yes, it’s a great business with tremendous potential for exponential growth.  But profit isn’t driving this partnership between Smith and Carl Saling, who himself became very emotional when he shared his family’s deep military roots …. and struggles with PTSD.  

As an investor in Hollister, you’ll love what this partnership can do for the company. As a human, you’ll love what this partnership is going to do for retired and active-duty military personnel. As a host, I’ve never been more proud of two guests on AGORACOM.  

Sit back and be prepared to watch the most powerful interview ever produced by AGORACOM.    

Please share this video on your social networks so that military personnel and their families can discover Tactical Relief.  

George

CLIENT FEATURE: Hollister Biosciences $HOLL.ca – Signed $20M LOI To Acquire Venom Extracts With $16.4M CAD In 2019 Revenue and 2.48M CAD in EBITDA $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 9:00 PM on Thursday, February 27th, 2020
HOLL:CSE /HOB:FRA

BREAKING: Signed $20,000,000 Letter of Intent To Acquire Venom Extracts (“Venom”)

HIGHLY ACCRETIVE $20,000,000 ACQUISITION

Venom Highlights

  • 2019 Est Revenue ~C$16.4M; EBITDA ~C$2.48M
  • 30% Of Acquisition Price Paid If Venom Revenues Hit $30,000,000 and $40,000,000 By DEC 31, 2021
  • Average revenue per gram YTD 2019 $CDN 14 and will continue to increase as vape cartridge mix grows ($CDN 30 per gram)
  • One Of Arizona’s Largest Producers Of Award-Winning Medical Cannabis Distillate
  • Acquisition Expected To Close By March 31, 2020 Subject To Due Diligence

An established brand in Arizona for high quality products in the wholesale and distillate marketplace. Venom is leveraging its brand and success to aggressively expand into other US states.

ACQUISITION TERMS

  • Hollister will acquire Venom Extracts for CDN$20,000,000 via Hollister stock
  • The stock price will be determined based on the greater of:
    • The 14-day VWAP (Volume Weighted Average Price) capped at $0.25 subsequent to announcing the transaction and $0.20
    • Once share price is established, 70% of the Payment Shares will be issued upon closing of the transaction
    • Remaining 30% of the Payment Shares will be issued when and if the following milestones have been met on or prior to December 31st, 2021

Per State Cash Flow Expectations

Planned State Additions

FIND OUT MORE!

Hub On AGORACOM / Corporate Profile / Read Release

FULL DISCLOSURE: Hollister Biosciences Inc. is an advertising client of AGORA Internet Relations Corp.

Empower Clinics $CBDT.ca – CBD consumption to rise across the treatment of neurological conditions $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 1:53 PM on Thursday, February 27th, 2020

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $1.4M USD (9 months ending Sept. 30, 2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 2,300 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025
  • Company to Create Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network

CBD consumption to rise across the treatment of neurological conditions

Research shows that CBD consumption for the treatment of neurological conditions is set to rise.

  • With an exponential rise in the availability of CBD products and public opinion towards it becoming more positive over the past decade, the consumption of the ingredient has exploded.
  • Global Market Insights, Inc., forecasts that global cannabidiol market size will be worth more than $89bn by 2026.

By: Health Europa

However, the industry will need to overcome the complex regulatory landscape as well as quality and supply challenges in the near future.

Over the past few years, cannabidiol, or CBD, has caught the public’s imagination as an ingredient presenting a range of health benefits when infused in various consumables. More and more individuals worldwide are now vouching for its effectiveness in terms of alleviating certain chronic illnesses and treating several health conditions.

CBD has conquered industry after industry, from pharmaceuticals to personal care and cosmetics, food and beverages, and nutraceuticals.

Cannabidiol is the legal and non-psychoactive counterpart of tetrahydro cannabidiol (THC), the chemical compound responsible for cannabis’s psychological effects. CBD is the second most-commonly used active ingredients of cannabis. The cannabinoid is derived directly from the hemp plant, a cousin of the cannabis plant, and forms an essential component of medical cannabis.

CBD regulatory landscape in Europe

Factors such as population growth, nationalised healthcare, GDP, and cultural historic use of CBD in many European countries make the continent an attractive market for global producers of both medical and retail cannabis-based products. Hemp cultivation in the region has witnessed a massive upsurge in recent years; the European Union (EU) constitutes more than 25% of the global hemp production.

In July last year Epidiolex CBD oil received a positive recommendation for marketing approval from the European Medicines Agency (EMA) for the treatment of seizures. EMA’s Human Medicines Committee (CHMP) approved the oral solution for use with clobazam for the treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in patients aged two or more.

The European Commission granted marketing approval to Epidyolex, the trade name for Epidiolex in Europe, in September 2019. Epidiolex is the only federally-approved CBD product in the U.S.

Additionally, the use of CBD in cosmetics is harmonised within the European Cosmetic Regulation 1223/2009. The regulation prohibits the use of cannabis and its derivatives in cosmetic products. Essentially, EU prohibits the use of CBD derived naturally from cannabis plants. However, the use of hemp-derived or synthetically-produced cannabidiol is approved.

Europe CBD market is poised to witness monumental growth in the forthcoming years on account of surging consumer demand for safe-strength CBD products that are easily available in their normal retail environments and cultivated, extracted, processed and labelled as per the European standards.

Growing burden of neurological diseases in Europe

Europe has witnessed a growing occurrence of various neurological conditions in recent years. These include epilepsy, migraine, stress, anxiety, and numerous sleeping disorders. An expanding geriatric population base indicates rising incidences of these conditions. Citing data from the European Brain Council, more than 220 million people in Europe suffer from at least one neurological condition, which is more than the populations of France, Germany, and the Great Britain combined.

Described below are some of the most prevalent neurological conditions in Europe and the effectiveness of CBD in their treatment.

  • Stress and anxiety – Nearly 25% of the European population suffers from stress, anxiety or depression each year. The effectiveness of CBD products as anti-anxiety nutraceuticals is backed with plenty of research, however there is still a long way to go. Several clinical trials have provided considerable evidence of cannabidiol’s usefulness for the treatment of generalised anxiety disorder (GAD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), social anxiety disorder, and panic disorder;
  • Migraine – Migraine currently affects more than 11% of the global population. The social societal burden of migraine in Europe is an approximately €27bn per year. While pain medications are known to help temporarily alleviate the symptoms of migraine, they can have several side-effects. Research concerning the use of cannabidiol for migraine is limited however a number of laboratory studies suggest that CBD oil may help reduce all types of acute and chronic pain, including migraine; and
  • Seizures – In Europe, close to six. million people suffer from epilepsy, while 15 million people will have at least one seizure at some point during their lifetime. Numerous research studies over the years have demonstrated the benefits and effectiveness of hemp-derived CBD products in patients with epilepsy who have not responded to traditional treatment.

Surging popularity of cannabidiol among boomers along with ongoing research and development into its potential health benefits will augment CBD market forecast. More and more boomers are adding CBD to their health regimes to help reduce stress and anxiety, get better sleep, and alleviate chronic pain. Increasing awareness towards the safety and efficacy of cannabidiol products will drive future CBD industry trends.

Source: https://www.healtheuropa.eu/cbd-consumption-to-rise-across-the-treatment-of-neurological-conditions/98105/

REPEAT: Mota Ventures $MOTA.ca Signs Letter of Intent for Merger with Stillcanna $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM at 9:10 AM on Thursday, February 27th, 2020
http://www.smallcapepicenter.com/Mota%20Square%20Logo%20For%20Blog.jpg
  • Stillcanna is a vertically integrated, European-based company with a focus on industrial-scale manufacturing of the highest quality CBD extracts
  • Stillcanna looks to become one of the largest producers of THC-free CBD extracts in Europe

VANCOUVER, BC / ACCESSWIRE / February 26, 2020 / Mota Ventures Corp. (CSE:MOTA)(OTC:PEMTF)(FRANKFURT:1WZGR) (“Mota“) and Stillcanna Inc. (STIL)(SCNNF)(A2PEWA) (“Stillcanna“) are pleased to announce that they have entered into a letter of intent (the “Letter of Intent“), dated effective February 25, 2020, pursuant to which Mota proposes to acquire all of the outstanding share capital of Stillcanna (the “Proposed Transaction“).

Strategic Merger

Mota is a globally-focused CBD product development and marketing company with established online retail brands in both the U.S. and Europe. Through its acquisition of First Class CBD, Mota has become a significant direct-to-consumer retail brand in the United States. In 2019, First Class CBD (then, a division of Unified Funding, LLC) realized approximately C$28.7 million in revenue with an EBITDA of approximately 12.5%.1 Mota’s successful e-commerce platform currently serves over 140,000 online customers and has generated over 400,000 leads in the United States. With the roll-out of First Class CBD’s proven e-marketing strategy throughout Europe, Mota believes that a merger with a high-quality CBD producer is of paramount importance in order to capture the large margins in the CBD-product supply chain.

Stillcanna is a vertically integrated, European-based company with a focus on industrial-scale manufacturing of the highest quality CBD extracts. Using proprietary extraction techniques and purpose-built equipment, Stillcanna looks to become one of the largest producers of THC-free CBD extracts in Europe. Stillcanna’s Polish extraction facility, NEXUS, features industrial-scale centrifugal chromatography equipment that allows for the production of bulk THC-free CBD distillate as well as custom Cannabinoid profiles. In February 2020, Stillcanna’s Romanian extraction facility, ORIGIN, which operates pursuant to a joint venture between Stillcanna and Dragonfly Biosciences Ltd., received approval from the Ministry of Health and the Anti-Drug Agency to become the first government recognized extraction facility in the country. To date C$23,000,000 has been invested by Stillcanna in the cultivation and extraction operations, with current cash on hand in Stillcanna of approximately C$7,000,000.

Stillcanna’s CBD extracts are key to unlocking additional value in Mota’s retail offerings in Europe. Through Stillcanna, Mota hopes to guarantee the supply of high-quality CBD for its expanding product line in Europe, while the large production capacity of NEXUS and ORIGIN will allow Mota to be a key supplier of legal CBD products in Europe.

“We are very excited to pursue a transaction with Stillcanna. The merger of this large-scale, high-quality CBD producer will fit brilliantly with Mota’s strategic expansion plan to vertically integrate operations in Europe while increasing profit margins in product offerings. Product awareness and availability are still quite limited in Europe, which presents an opportunity for Mota to further establish its brands in a market that is expected to experience rapid growth in the near term. With the Stillcanna merger, we’re putting together a team that can create, market and sell consumer CBD products to European customers,” stated Ryan Hoggan, CEO of Mota.

“Combining a company that has established brands and direct-to-consumer sales channels with one that has proven CBD extraction expertise makes perfect sense to us,” commented Jason Dussault, CEO of Stillcanna. “The wholesale landscape for CBD has changed dramatically in the past year, and the creation of a seed-to-consumer CBD company in the growing European market creates a direct path to profitability. This merger completes the circle for Stillcanna, evolving from a seed to CBD concentrate company to a seed to retail sales company.”

Merger Details

Under the terms of the Proposed Transaction, Mota would acquire all of the outstanding share capital of Stillcanna by way of a statutory plan of arrangement under the Business Corporations Act of British Columbia Canada. Shareholders of Stillcanna (the “Stillcanna Shareholders“) would receive one common share of Mota for every 1.8 common shares of Stillcanna held at the time of exchange (the “Exchange Ratio“). Based on the current outstanding common share capital of Stillcanna, it is anticipated that Mota would issue approximately 61,597,082 Mota shares to complete the Proposed Transaction.

Upon completion of the Proposed Transaction: (i) all outstanding incentive stock options of Stillcanna will be exchanged for options to purchase Mota shares on the basis of the Exchange Ratio and will thereafter be subject to the incentive stock option plan of Mota; and (ii) all unexercised share purchase warrants of Stillcanna will be exchanged for warrants to purchase Mota shares on the basis of the Exchange Ratio and will expire in accordance with their current expiry dates.

Mota and Stillcanna are at arms-length. The Proposed Transaction does not constitute a reverse-takeover of Mota, nor is it expected to result in a change of control of Mota within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. Upon completion of the Proposed Transaction, there will be no changes to the management or the board of directors of Mota and it is expected that members of management and the board of Stillcanna will continue to assist in relation to the management of Stillcanna’s business.

Completion of the Proposed Transaction remains subject to a number of conditions, including, but not limited to: (i) satisfactory completion of due diligence; (ii) negotiation of definitive, legally-binding documentation; (iii) receipt of any required regulatory approvals, including the court; (iv) the approval of the Stillcanna Shareholders; (v) receipt of a satisfactory fairness opinion in respect of the Proposed Transaction; (vi) Stillcanna having arranged to amend the terms of certain existing employment and consulting engagements; (vii) shareholders of Stillcanna holding at least 40,000,000 of the outstanding share capital of Stillcanna having agreed to the terms of a pooling arrangement restricting their ability to trade one-half of the Mota shares they receive for a period of six months following completion of the Proposed Transaction; (viii) Stillcanna having positive working capital of not less than C$6,000,000, after taking into account all expenses associated with the Proposed Transaction; and (ix) Mota completing a private placement of units to raise gross proceeds of not less than C$5,000,000 (the “Mota Financing“). The Proposed Transaction cannot be completed until these conditions are satisfied. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.

The proposed Mota Financing will consist of units at a price of C$0.45 per unit, with each unit comprised of one Mota common share and one share purchase warrant of Mota. Each such warrant will be exercisable to purchase one common share of Mota at a price of C$0.60 for a period of two years. All securities to be issued in connection with the Mota Financing will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws. Mota anticipates paying finders fees to certain eligible parties who have introduced subscribers to the Mota Financing.

The board of directors of each of Mota, and Stillcanna, have unanimously approved the Letter of Intent. Further information about the Proposed Transaction will be included in subsequent press releases when available.

About Mota Ventures Corp.

Mota is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota.

About Stillcanna Inc.

Stillcanna is a Canadian early-stage life sciences company focused on the large-scale manufacturing of CBD in Europe using its proprietary intellectual property. Stillcanna has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly Biosciences LLC, a United Kingdom-based supplier of CBD. Stillcanna also recently completed the acquisition of Olimax NT SP.Z.O.O., a multi-generational hemp agricultural firm that is expected to increase market share in the European CBD industry.

On behalf of Mota Ventures Corp.

Ryan Hoggan
Chief Executive Officer

On behalf of Stillcanna Inc.

Jason Dussault

Chief Executive Officer

For more information visit

www.motaventuresco.com or contact:

Investor Relations

[email protected]
+1.604.423.4733

For more information visit www.stillcanna.com or contact:

Mauricio Inzunza
[email protected]

Mota Ventures $MOTA.ca Signs Letter of Intent for Merger with Stillcanna $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca

Posted by AGORACOM at 6:10 PM on Wednesday, February 26th, 2020
http://www.smallcapepicenter.com/Mota%20Square%20Logo%20For%20Blog.jpg
  • Stillcanna is a vertically integrated, European-based company with a focus on industrial-scale manufacturing of the highest quality CBD extracts
  • Stillcanna looks to become one of the largest producers of THC-free CBD extracts in Europe

VANCOUVER, BC / ACCESSWIRE / February 26, 2020 / Mota Ventures Corp. (CSE:MOTA)(OTC:PEMTF)(FRANKFURT:1WZGR) (“Mota“) and Stillcanna Inc. (STIL)(SCNNF)(A2PEWA) (“Stillcanna“) are pleased to announce that they have entered into a letter of intent (the “Letter of Intent“), dated effective February 25, 2020, pursuant to which Mota proposes to acquire all of the outstanding share capital of Stillcanna (the “Proposed Transaction“).

Strategic Merger

Mota is a globally-focused CBD product development and marketing company with established online retail brands in both the U.S. and Europe. Through its acquisition of First Class CBD, Mota has become a significant direct-to-consumer retail brand in the United States. In 2019, First Class CBD (then, a division of Unified Funding, LLC) realized approximately C$28.7 million in revenue with an EBITDA of approximately 12.5%.1 Mota’s successful e-commerce platform currently serves over 140,000 online customers and has generated over 400,000 leads in the United States. With the roll-out of First Class CBD’s proven e-marketing strategy throughout Europe, Mota believes that a merger with a high-quality CBD producer is of paramount importance in order to capture the large margins in the CBD-product supply chain.

Stillcanna is a vertically integrated, European-based company with a focus on industrial-scale manufacturing of the highest quality CBD extracts. Using proprietary extraction techniques and purpose-built equipment, Stillcanna looks to become one of the largest producers of THC-free CBD extracts in Europe. Stillcanna’s Polish extraction facility, NEXUS, features industrial-scale centrifugal chromatography equipment that allows for the production of bulk THC-free CBD distillate as well as custom Cannabinoid profiles. In February 2020, Stillcanna’s Romanian extraction facility, ORIGIN, which operates pursuant to a joint venture between Stillcanna and Dragonfly Biosciences Ltd., received approval from the Ministry of Health and the Anti-Drug Agency to become the first government recognized extraction facility in the country. To date C$23,000,000 has been invested by Stillcanna in the cultivation and extraction operations, with current cash on hand in Stillcanna of approximately C$7,000,000.

Stillcanna’s CBD extracts are key to unlocking additional value in Mota’s retail offerings in Europe. Through Stillcanna, Mota hopes to guarantee the supply of high-quality CBD for its expanding product line in Europe, while the large production capacity of NEXUS and ORIGIN will allow Mota to be a key supplier of legal CBD products in Europe.

“We are very excited to pursue a transaction with Stillcanna. The merger of this large-scale, high-quality CBD producer will fit brilliantly with Mota’s strategic expansion plan to vertically integrate operations in Europe while increasing profit margins in product offerings. Product awareness and availability are still quite limited in Europe, which presents an opportunity for Mota to further establish its brands in a market that is expected to experience rapid growth in the near term. With the Stillcanna merger, we’re putting together a team that can create, market and sell consumer CBD products to European customers,” stated Ryan Hoggan, CEO of Mota.

“Combining a company that has established brands and direct-to-consumer sales channels with one that has proven CBD extraction expertise makes perfect sense to us,” commented Jason Dussault, CEO of Stillcanna. “The wholesale landscape for CBD has changed dramatically in the past year, and the creation of a seed-to-consumer CBD company in the growing European market creates a direct path to profitability. This merger completes the circle for Stillcanna, evolving from a seed to CBD concentrate company to a seed to retail sales company.”

Merger Details

Under the terms of the Proposed Transaction, Mota would acquire all of the outstanding share capital of Stillcanna by way of a statutory plan of arrangement under the Business Corporations Act of British Columbia Canada. Shareholders of Stillcanna (the “Stillcanna Shareholders“) would receive one common share of Mota for every 1.8 common shares of Stillcanna held at the time of exchange (the “Exchange Ratio“). Based on the current outstanding common share capital of Stillcanna, it is anticipated that Mota would issue approximately 61,597,082 Mota shares to complete the Proposed Transaction.

Upon completion of the Proposed Transaction: (i) all outstanding incentive stock options of Stillcanna will be exchanged for options to purchase Mota shares on the basis of the Exchange Ratio and will thereafter be subject to the incentive stock option plan of Mota; and (ii) all unexercised share purchase warrants of Stillcanna will be exchanged for warrants to purchase Mota shares on the basis of the Exchange Ratio and will expire in accordance with their current expiry dates.

Mota and Stillcanna are at arms-length. The Proposed Transaction does not constitute a reverse-takeover of Mota, nor is it expected to result in a change of control of Mota within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. Upon completion of the Proposed Transaction, there will be no changes to the management or the board of directors of Mota and it is expected that members of management and the board of Stillcanna will continue to assist in relation to the management of Stillcanna’s business.

Completion of the Proposed Transaction remains subject to a number of conditions, including, but not limited to: (i) satisfactory completion of due diligence; (ii) negotiation of definitive, legally-binding documentation; (iii) receipt of any required regulatory approvals, including the court; (iv) the approval of the Stillcanna Shareholders; (v) receipt of a satisfactory fairness opinion in respect of the Proposed Transaction; (vi) Stillcanna having arranged to amend the terms of certain existing employment and consulting engagements; (vii) shareholders of Stillcanna holding at least 40,000,000 of the outstanding share capital of Stillcanna having agreed to the terms of a pooling arrangement restricting their ability to trade one-half of the Mota shares they receive for a period of six months following completion of the Proposed Transaction; (viii) Stillcanna having positive working capital of not less than C$6,000,000, after taking into account all expenses associated with the Proposed Transaction; and (ix) Mota completing a private placement of units to raise gross proceeds of not less than C$5,000,000 (the “Mota Financing“). The Proposed Transaction cannot be completed until these conditions are satisfied. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.

The proposed Mota Financing will consist of units at a price of C$0.45 per unit, with each unit comprised of one Mota common share and one share purchase warrant of Mota. Each such warrant will be exercisable to purchase one common share of Mota at a price of C$0.60 for a period of two years. All securities to be issued in connection with the Mota Financing will be subject to a four-month-and-one-day statutory hold period in accordance with applicable securities laws. Mota anticipates paying finders fees to certain eligible parties who have introduced subscribers to the Mota Financing.

The board of directors of each of Mota, and Stillcanna, have unanimously approved the Letter of Intent. Further information about the Proposed Transaction will be included in subsequent press releases when available.

About Mota Ventures Corp.

Mota is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota.

About Stillcanna Inc.

Stillcanna is a Canadian early-stage life sciences company focused on the large-scale manufacturing of CBD in Europe using its proprietary intellectual property. Stillcanna has signed an initial extraction contract in Europe to be the exclusive extractor for Dragonfly Biosciences LLC, a United Kingdom-based supplier of CBD. Stillcanna also recently completed the acquisition of Olimax NT SP.Z.O.O., a multi-generational hemp agricultural firm that is expected to increase market share in the European CBD industry.

On behalf of Mota Ventures Corp.

Ryan Hoggan
Chief Executive Officer

On behalf of Stillcanna Inc.

Jason Dussault

Chief Executive Officer

For more information visit

www.motaventuresco.com or contact:

Investor Relations

[email protected]
+1.604.423.4733

For more information visit www.stillcanna.com or contact:

Mauricio Inzunza
[email protected]

Empower Clinics $CBDT.ca – CBD Sales Predicted to Grow, #cannabis and #cannabidiol #CBD products reached $14 billion in 2019 $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 12:05 PM on Wednesday, February 26th, 2020

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $1.4M USD (9 months ending Sept. 30, 2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 2,300 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025
  • Company to Create Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network

CBD Sales Predicted to Grow, Market Analysis Finds

  • U.S. retail sales of cannabis and cannabidiol (CBD) products reached $14 billion in 2019
  • On pace to increase 18% per year to $33 billion in 2024

By WholeFoods Magazine Staff

Rockville, MD—U.S. retail sales of cannabis and cannabidiol (CBD) products reached $14 billion in 2019, and are on pace to increase 18% per year to $33 billion in 2024, according to data published in a new report from Packaged Facts titled Cannabis and CBD: U.S. Retail Market Trends and Opportunities.

The most common delivery format for cannabis, the flower—smoked as buds or as cigarettes—accounts for nearly 40% of retail sales, according to a press release. Vaporizer cartridges with concentrated THC or CBD compounds takes the second largest share, but it’s falling, as concerns about vaping-related lung illnesses rise. Edibles and topicals are predicted to rise, and to rise quickly, as they stand to benefit the most from legalization of hemp-based CBD; major retailers are already offering CBD-infused food and beverages, as well as CBD-infused cosmetics.

The report analyzes cannabis and cannabis-related retail trends and opportunities in the U.S., with a focus on multi-state cannabis dispensary operators and food and beverage introductions, as well as market trends by state. It also includes a detailed analysis of cannabis-related legal and regulatory trends at the federal and state levels. The report can be purchased here.

Source: https://wholefoodsmagazine.com/suppliers/news-suppliers/cbd-sales-predicted-to-grow-market-analysis-finds/

AGORACOM Welcomes Hollister Biosciences With A $20 MILLION LOI Signed To Acquire Venom Extracts With $CDN 16.4 million In Revenue and $CN 2.48 million in EBIDTA

Posted by AGORACOM-JC at 6:39 PM on Tuesday, February 25th, 2020

HOLL:CSE / HOB:FRA

 www.hollistercannabisco.com

BREAKING: Signed $20,000,000 Letter of Intent To Acquire Venom Extracts (“Venom”)

HIGHLY ACCRETIVE $20,000,000 ACQUISITION

Venom Highlights

  • 2019 Est Revenue ~C$16.4M; EBITDA ~C$2.48M
  • 30% Of Acquisition Price Paid If Venom Revenues Hit $30,000,000 and $40,000,000 By DEC 31, 2021
  • Average revenue per gram YTD 2019 $CDN 14 and will continue to increase as vape cartridge mix grows ($CDN 30 per gram)
  • One Of Arizona’s Largest Producers Of Award-Winning Medical Cannabis Distillate
  • Acquisition Expected To Close By March 31, 2020 Subject To Due Dilligence

An established brand in Arizona for high quality products in the wholesale and distillate marketplace. Venom is leveraging its brand and success to aggressively expand into other US states.

ACQUISITION TERMS

  • Hollister will acquire Venom Extracts for CDN$20,000,000 via Hollister stock
  • The stock price will be determined based on the greater of:
    • The 14-day VWAP (Volume Weighted Average Price) capped at $0.25 subsequent to announcing the transaction and $0.20
    • Once share price is established, 70% of the Payment Shares will be issued upon closing of the transaction
    • Remaining 30% of the Payment Shares will be issued when and if the following milestones have been met on or prior to December 31st, 2021

Hollister Highlights Of Current Operations:

  • Hollister’s products are now present in 220 of 600 California dispensaries.
  • Own’s California’s #1 hash infused pre-roll “HashBone”
  • Vision is to capitalize on this success to become the sought after premium brand portfolio of Cannabis across multiple states and Hemp nationwide
  • Major LOI, Joint Ventures and Licensing Agreements Support Proof Of This Vision
  • “Easy Riders” – Milliions Of Global Followers
  • “Tactical Relief” – Veteran Founded, Hemp Based CBD Brand With Nation Wide Members  
  • “Tommy Chong” – Exclusive Manufacture & Distribution Of Tommy Chong’s Cannabis (TM) Full Spectrum Elixir 1:1

“I only partner with the best-in-class companies and I am really pleased to have the Hollister Cannabis Co. bring their amazing Tommy Chong’s Cannabis™ Full Spectrum Elixir to the market for me”. 

– Tommy Chong

KEY JOINT VENTURES AND PARTNERSHIPS DETAILS 

LOI for a proposed offtake agreement with Mountain Financial Solutions LLC 

  • Hollister will purchase 1,000 pounds of hemp from Mountain Financial (unique high CBD hemp strains ) for use in various smokable hemp products – specifically, Rebel Hemp Company’s premium hemp pre-rolls.

Licensing agreement with Tommy Chong to manufacture and distribute Tommy Chong’s Cannabis™

  • Full Spectrum Elixir 1:1.
  • The tincture, features a 1:1 ratio of THC to CBD, recognized for its medicinal properties
  • Distributed exclusively by Indus and is anticipated to be in-dispensaries throughout California by March 01, 2020.
  • Anticipating producing up to 25,000 units of  during the 1st 12 months with an estimated retail price of $70 per unit 

LOI with ER71 USA Inc. (“Easyriders”)  an iconic brand with millions of followers globally,  have entered into LOI to complete a joint venture agreement

  • Upon completion of the Joint Venture, Hollister and Easyriders will collaborate on the development and marketing of co-branded hemp based everyday premium product lines.
  • Pre-rolled products using hemp

JV will further explore the development and marketing of additional product SKU’s for hemp-based

  • Edibles
  • Vapes
  • Topicals
  • beverages.

Revenue generated on the co-branded product lines will be shared 50:50 between Easyriders and Hollister. 

Hollister Biosciences Inc. and Veteran Based Tactical Relief Enter into Letter of Intent for Proposed Joint Venture Agreement

  • Upon completion of the Agreement, Hollister and Tactical Relief will collaborate on the development and marketing of cannabis tinctures throughout the California market
  • Branded under Tactical Relief, the first cannabis tincture to be manufactured will feature a 20:1 ratio of THC to CBD, recognized for its medicinal properties in treating PTSD
  • Will be distributed exclusively by Hollister’s distribution partner, Indus Holdings Inc.
Hollister Biosciences Inc. and Tactical Relief Enter into Letter of Intent for Proposed Joint Venture Agreement (CNW Group/Hollister Biosciences Inc.)

Hollister Currently Manufactures The Following Products:

  • hash
  • hash infused products
  • tinctures
  • crumble infused products
  • Pre-rolls           
  • Vape Products   
  • Pet CBD 
  • Cannabis Concentrate   
  • Brewed Hemp Beverages
  • Premium Hemp Pre-Rolls
  • other cannabis products

HashBones

  • Hashbones are a pre-roll made from 75% cannabis flower blended in small batches with 25% bubble hash
  • Results in a more potent pre-roll, also maintains the integrity of the cannabis
  • Terpenes are preserved in the bubble hash production process
  • Bubble hash is made without solvents or chemicals and is one of the cleanest concentrates available on the market
  • Hollister’s trusted and highly rated brand of pre-rolls, sold via third-party retailers

Mighty Meds

  • Acquired Mighty Meds as its vape brand
  • Company’s vape products are manufactured from pure THC distillate and plant-based terpenes and do not use any additives that have been linked to health issues.
  • San Diego based
  • Produces discreet, disposable, health conscious vape cartridges and other products

Purity Petibles

  • Purity Petibles 20:1 CBD pet tincture is manufactured using full spectrum CBD, organic MCT Oil derived from coconuts and chicken flavor
  • The MCT Oil and chicken flavor used in Purity Petibles is food grade

Rebel Tea

  • Brewed with high-quality, American-grown hemp and containing fifteen milligrams of whole-plant full-spectrum phytocannabinoids, Rebel Tea offers consumers a refreshing THC-free beverage. Rebel Tea’s innovative formula features exclusively organic ingredients paired with light flavoring from natural lemon and cane sugar.

NanoPure

NanoPure, nano-emulsified cannabis concentrate which will be sold both:

  • Wholesale as an ingredient for other companies and
  • power products for Hollister Cannabis Co. 

DISTRIBUTION

  • Hollister has an exclusive distribution agreement in place with Indus Holdings (CSE: INDS).
  • Indus is the licensed California distributor that operates the WAYV platform.
  • Indus currently manages all of Hollister’s product fulfilment obligations, allowing Hollister to focus its efforts on production and marketing.
  • Indus provides Hollister with full brand representation by utilizing its 15 sales reps to represent Hollister’s product to the California marketplace. 
  • Through Indus, Hollister’s products are now present in 220 dispensaries throughout California.

US CANNABIS MARKET STATS

CALIFORNIA CANNABIS MARKET STATS

HEMP

The Company intends to move into the hemp market.  While cannabis is still restricted by state regulations, CBD is not. We plan on leveraging the brand by distributing hemp and CBD versions of our products nationwide. We will strive to have the Rebel Hemp Co brand touch every corner of the country.

CORPORATE STRUCTURE

Hollister develops quality branded cannabinoid-based and hemp-based consumer goods and products for large-scale distribution through two companies: Hollister Cannabis Co. and Rebel Hemp Company.

INTERVIEW: Hollister $HOLL.ca Signs $20M LOI To Acquire Venom With $16.4M Revenue & $2.48M EBITDA $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 4:00 PM on Tuesday, February 25th, 2020

At a time when Cannabis stocks are struggling and in a massive state of flux, due to an inability to actually deliver real businesses, Hollister Biosciences (HOLL:CSE) has been quietly building a real business, products, revenue and customers in 220 of California’s 600 dispensaries …. and growing, including California’s #1 hash infused pre-roll “Hashbone”.  

In addition to that, Hollister has also signed LOI’s, JV’s and licensing deals with major partners with massive nationwide and even global audiences launching in the next couple of months.  We’ll save details of those for another day but suffice it to say one of those partners is the world renowned Tommy Chong (of Cheech & Chong) who stated:

“I only partner with the best-in-class companies and I am really pleased to have the Hollister Cannabis Co. bring their amazing Tommy Chong’s Cannabis™ Full Spectrum Elixir to the market for me”.   

If that was all Hollister had going, they’d be in great shape with a super bright future and better than most Cannabis companies (small and large) who can’t even get product out the door.  

BUT THERE’S MORE – THE $20,000,000 ACQUISITION THAT COMES WITH $CDN 16.4M REVENUE & $CDN 2.48M EBITDA  

Earlier today, Hollister announced an LOI to acquire Venom Extracts, one of Arizona’s largest producers of Award-Winning Medical Cannabis Distillate. Just how good is Venom? In 2019, Venom generated $CDN 16.4M in revenue and $CDN 2.48M EBITDA in 2019 (subject to due diligence confirmation) … and all of that was just from the state of Arizona! Venom CEO Mason Cave and his team have aggressive plans to expand its brand and success into other states, including California as it benefits from Hollister’s distribution into 220 dispensaries.  

If you think “growth talk is cheap” (which is often the case), consider the fact that 30% of Venom’s $20,000,000 sale price kicks in if/when revenues hit $CDN 30,000 and $CDN 40,000 …. by December 31, 2021.  In my experience, companies joining forces don’t include such terms if there isn’t a reasonable expectation for hitting those numbers.  It doesn’t guarantee it but you can bet they have good reason to believe Venom sales will get to one or both of those numbers in just 21 months from now.  

If you’re looking for Cannabis companies that are going to survive and thrive over this next decade, then grab your favourite beverage and watch this interview with Hollinger President, Alex Somjen.  

We loved what we heard and look forward to your feedback in Hollister’s CEO Verified Forum below!

https://agoracom.com/ir/HollisterBiosciences

Empower Clinics $CBDT.ca to Create #Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 6:10 AM on Tuesday, February 25th, 2020
  • Company intends to utilize its database of 165,000 patients to further psilocybin research, develop new products and partner with global leaders in the field
  • “Empower is uniquely positioned to immediately impact research, develop new products and bring advancements to plant-based therapies, under a framework of rapidly increasing awareness and a movement toward decriminalization of psychedelic treatment options.” said Steven McAuley, Chairman & CEO of Empower

VANCOUVER, BC / February 25, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTC:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented life sciences company is pleased to announce it intends to leverage its existing clinic network, the developing franchise brand, its 165,000 patients and product development capability, to create psilocybin and psychedelics subsidiaries.

The Company has been conducting market research on advancements in psilocybin and psychedelics in North America and globally, along with building the business case internally on how to create greater shareholder value, utilizing Company assets that include clinics, patients, physicians and technology.

“There is an undeniable mental health crisis in our country and around the world, that has an ever-increasing, devastating affect on our society.” said Steven McAuley, Chairman & CEO of Empower. “Empower is uniquely positioned to immediately impact research, develop new products and bring advancements to plant-based therapies, under a framework of rapidly increasing awareness and a movement toward decriminalization of psychedelic treatment options.”

Studies conducted by nationally and internationally recognized medical institutions indicate that psilocybin has shown efficacy, tolerability, and safety in the treatment of a variety of mental health conditions, including but not limited to addiction, depression, anxiety disorders, and end-of-life psychological distress.

“Over the past seven years, we have assisted over one hundred thousand patients obtain access to alternative health care and medicinal cannabis. The provision of legal access to psilocybin therapies are perfectly in-line with our philosophy of providing a Scientific Approach to Alternative Medicine“, said Dustin Klein, SVP Business Development and Director, Empower Clinics Inc. “Clinical trials have shown that psilocybin therapies provide tremendous help with conditions we see everyday in our clinics. It is our responsibility, to make sure we are providing the most up-to-date alternative therapies to our patients and our community.”

The mental health crisis could cost the world $16 trillion by 2030 and according to Future Market Insights; the global behavioral health (non-pharmacological) market is expected to be valued at US$156 billion by 2028.

The United States Food and Drug Administration has determined that preliminary clinical evidence indicates psilocybin may demonstrate substantial improvement over other available therapies for treatment-resistant depression; and granted a Breakthrough Therapy designation for a treatment that uses psilocybin as a therapy for such depression.

The Company also announces it has issued to Haywood Securities Inc., 4,000,000 common shares of the Company (the “Work Fee Shares”) under the financial advisory agreement dated September 25, 2019 (the “Agreement”) based on Haywood Securities Inc. completing the final written SWOT analysis. The shares issued are priced at fair market value of the common shares of the Corporation as at the date of issuance of the Work Fee Shares.

ABOUT EMPOWER

Empower is a vertically-integrated health & wellness brand with it’s first hemp-derived CBD extraction facility under development, the Company produces its proprietary line of cannabidiol (CBD) based products and distributes products through company owned and franchised clinics, with wholesale partnerships, online channels and with new retail opportunities nationwide in the U.S. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
Chairman & CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Hollister Biosciences $HOLL.ca Signs Letter of Intent to Acquire Venom Extracts With $16.4 Million In Revenue And $2.48 Million EBITDA $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 6:02 AM on Tuesday, February 25th, 2020
  • Company signed a Letter of Intent to acquire Venom Extracts
  • One of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.
  • Venom Extracts reports having generated CDN$ 16.4 million in revenue and CDN$ 2.48 million in EBIDTA from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges.

Hollister Biosciences Inc., the creator of California’s #1 hash-infused pre-roll HashBone, enters into Letter of Intent to acquire Venom Extracts, one of Arizona’s largest producers of award-winning medical cannabis distillate and related products

VANCOUVER, Feb. 25, 2020 – Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a vertically integrated cannabis branding company with products in 220 dispensaries throughout California, is pleased to announce that the Company signed a Letter of Intent (“LOI“) on February 20th, 2020 to acquire Venom Extracts ( “Venom“), one of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.

HIGHLY ACCRETIVE $20,000,000 ACQUISITION

For the year ended December 31, 2019, Venom Extracts reports having generated CDN$ 16.4 million in revenue and CDN$ 2.48 million in EBIDTA from its product line of Cannabis Concentrates, P.H.O Concentrates and Cartridges. Hollister cautions that revenue and EBITDA figures have not yet been audited and are based on reports prepared by Venom management. Though Hollister believes the figures to be highly reliable, their audit will be part of the due diligence before closing.   

The all stock purchase price is anticipated to be CDN$ 20,000,000, with 70% to be paid upfront and 30% to be paid upon milestone achievements. The acquisition is expected to close by March 31, 2020 subject to normal course due diligence. 

 “Venom has established itself as a leading extraction operation with a prominent brand in the Arizona marketplace”, said Carl Saling, Founder and CEO of Hollister Biosciences Inc.  “We feel this acquisition will present a great deal of opportunity for synergy between Hollister and Venom, providing avenues for both companies into the Arizona, California and additional marketplaces for cannabis products.  Venom Extracts has a highly skilled and experienced management team with a track record for operational excellence.  This transaction is highly accretive and represents a fundamental part of the future growth of both companies.”

LOI TERMS

The terms of the LOI, which will be formalized by a definitive agreement on closing, are as follows:

  • The Company will acquire Venom Extracts for CDN$20,000,000 with such payment to be issued in Hollister common stock (the “Payment Shares“)
  • The stock price will be determined based on the greater of:
    • The 14-day VWAP (Volume Weighted Average Price) capped at $0.25 subsequent to announcing the transaction and $0.20
  • Once the share price is established, 70% of the Payment Shares will be issued upon closing of the transaction, subject to hold periods.
  • The remaining 30% of the Payment Shares will be issued when and if the following milestones have been met on or prior to December 31st, 2021:
    • 20% (of the total number of Payment Shares) will be issued when revenue of Venom Extracts reaches CDN$ 30,000,000 (calculated in accordance with IFRS from January 1, 2020).
    • 10% (of the total number of Payment Shares) will be issued when revenue of Venom Extracts reaches CDN$ 40,000,000(calculated in accordance with IFRS from January 1, 2020).

“We are very pleased to be entering into this transaction with Hollister”, shared Mason Cave, CEO of Venom Extracts.  “The opportunities for resource and capability sharing between the two companies are plentiful.  This also represents a more expeditious avenue for us into the large and rapidly growing California marketplace.  Hollister has an excellent management team in place and has established itself as a sought-after brand house of popular cannabis and hemp products in California.  We feel that our contribution on the extraction side will help diversify Hollister’s product offering and continue to build out the brand equity of both companies across multiple state and eventually global marketplaces”

In association with the arm’s length transaction, Hollister will not be assuming any long-term debt, a new control position will be created and there is no change in Management, or the Board of Directors of Hollister being contemplated at this time.

Finder’s fees will be payable in accordance with the policies of the Canadian Securities Exchange.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a vertically integrated cannabis company with multiple, high-quality products now carried in 220 of Indus Holdings (CSE: INDS), Hollister’s exclusive distribution partner’s 600 dispensaries. This level of penetration is expected to grow as the Company accelerates its seed to shelf, high margin business and product development model.

Capitalizing on this success, Hollister’s vision is to become the sought-after premium brand portfolio of innovative, high quality cannabis across multiple states and hemp products nationwide.

Our wholly owned California subsidiary, Hollister Cannabis Co, is the 1st state and locally licensed Cannabis Company in the City of Hollister, California, the birthplace of the “American Biker” from which we embrace the outlaw roots of Hollister to drive our Company fearlessly down the road of success.

Products from Hollister Cannabis Co. include HashBone, the brand’s premier artisanal hash-infused pre-roll ranked as California’s #1 hash infused pre-roll, along with solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures.

Website:  www.hollistercannabisco.com 

About Venom Extracts

Venom Extracts is one of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.  With an experienced management team and unparalleled reputation for quality, Venom Extracts prides itself as a differentiated extraction company by producing legal Marijuana products at a price point that allows retailers to generate higher profits.  Focused on proprietary efficiencies, the Company is able to produce more product per square foot than its competition, maintaining lower costs and risks than a typical extraction company. The company’s expansion strategy is centered on entering new markets/states that are approved for medical cannabis use and/or approved or have a reasonable expectation to be approved for recreational use in the near future. 

Website:  www.venomextracts.com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile onwww.sedar.com

million-ebitda-301010229.html

SOURCE Hollister Biosciences Inc.